Companies › SOFIE
1 active drug program in 2 registered trials: 2 Phase 3; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [18F]FAPI-74 FAP-targeting radioactive diagnostic agent for PET imaging | FAP | Phase 3 | Esophageal Cancer; Pancreatic Ductal Adenocarcinoma (PDAC) | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07217704 | [18F]FAPI-74 | Phase 3 | Esophageal Cancer | Oncology | Aug 2027 |
| NCT07217717 | [18F]FAPI-74 | Phase 3 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Dec 2027 |
Blue Earth Diagnostics Chengdu New Radiomedicine Technology LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.